Literature DB >> 1363009

Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.

R Lehmann1, B von Beust, E Niederer, M A Condrau, W Fierz, A Aubert, C D Ackley, M D Cooper, M B Tompkins, H Lutz.   

Abstract

In a previous experiment a group of 15 specified pathogen free (SPF) cats were experimentally infected with a Swiss isolate of feline immunodeficiency virus (FIV). A group of 15 SPF cats served as FIV negative controls. Nine cats of each group were vaccinated with a recombinant feline leukemia virus (FeLV) vaccine, six cats in each group with a placebo vaccine. All vaccinated cats developed high antibody titers to FeLV and were protected against subsequent FeLV challenge infection. In both control groups five of six cats became persistently infected with FeLV. Unexpectedly, the primary immune response to the vaccine antigen was significantly higher in the FIV positive group than in the FIV negative. The secondary response was stronger in the FIV negative cats. The goal of the present investigation was to further study the immune response in these 30 cats. They were immunized twice with the synthetic peptide L-tyrosine-L-glutamic acid-poly(DL-alanine)-poly(L-lysine) (TGAL) 21 days apart. Blood samples were collected on four occasions during the immunization process. They were tested for antibodies to TGAL, complete blood cell counts and CD4+, CD8+ and pan-T-lymphocyte counts. The following observations were made: (1) in contrast to the FeLV vaccine experiment, the primary immune response to TGAL was not significantly stronger in the FIV positive cats when tested by enzyme-linked immunosorbent assay (2). The absolute size of the CD4+ lymphocyte population was distinctly smaller in the FIV positive than in the FIV negative cats. The lowest CD4+ values were found in the dually FIV/FeLV infected cats. (3) A population of CD8+ lymphocytes was identified that was characterized by a distinctly weaker fluorescence. The size of this population increased in FIV positive and decreased in FIV negative cats during the TGAL immunization experiment. (4) The CD4+:CD8+ ratio increased in FIV negative cats during TGAL immunization from 1.9 to 2.3. In contrast, in FIV positive animals the CD4+:CD8+ ratio decreased significantly from 1.9 to 1.3 during the same period. From these and earlier data it was concluded that in short-term FIV infection the immune response to T-cell dependent antigens may be increased over that of the controls. Immune suppression develops gradually with duration of the infection. The significant drop of the CD4+:CD8+ ratio over a 5 week immunization period suggests that antigenic stimulation may accelerate the development of immune suppression in FIV positive cats. If this is a general feature, FIV infection may provide a particularly interesting model for studying the pathogenesis of AIDS.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1363009     DOI: 10.1016/0165-2427(92)90132-a

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  12 in total

1.  Suppression of feline immunodeficiency virus replication in vitro by a soluble factor secreted by CD8+ T lymphocytes.

Authors:  J N Flynn; C A Cannon; D Sloan; J C Neil; O Jarrett
Journal:  Immunology       Date:  1999-02       Impact factor: 7.397

2.  Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: hematology, clinical chemistry, and lymphocyte subsets.

Authors:  R Hofmann-Lehmann; E Holznagel; P Ossent; H Lutz
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

Review 3.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

4.  The role of in vitro-induced lymphocyte apoptosis in feline immunodeficiency virus infection: correlation with different markers of disease progression.

Authors:  E Holznagel; R Hofmann-Lehmann; C M Leutenegger; K Allenspach; S Huettner; U Forster; E Niederer; H Joller; B J Willett; U Hummel; G L Rossi; J Schüpbach; H Lutz
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

Review 5.  Feline immunodeficiency virus latency.

Authors:  Samantha J McDonnel; Ellen E Sparger; Brian G Murphy
Journal:  Retrovirology       Date:  2013-07-06       Impact factor: 4.602

6.  Co-infection with feline retrovirus is related to changes in immunological parameters of cats with sporotrichosis.

Authors:  Luisa Helena Monteiro de Miranda; Marina Meli; Fátima Conceição-Silva; Marilisa Novacco; Rodrigo Caldas Menezes; Sandro Antonio Pereira; Sarah Sugiarto; Érica Guerino Dos Reis; Isabella Dib Ferreira Gremião; Regina Hofmann-Lehmann
Journal:  PLoS One       Date:  2018-11-30       Impact factor: 3.240

Review 7.  Feline immunodeficiency virus infection: an overview.

Authors:  K Hartmann
Journal:  Vet J       Date:  1998-03       Impact factor: 2.688

8.  Therapeutic Efficacy of Fresh, Autologous Mesenchymal Stem Cells for Severe Refractory Gingivostomatitis in Cats.

Authors:  Boaz Arzi; Emily Mills-Ko; Frank J M Verstraete; Amir Kol; Naomi J Walker; Megan R Badgley; Nasim Fazel; William J Murphy; Natalia Vapniarsky; Dori L Borjesson
Journal:  Stem Cells Transl Med       Date:  2015-11-18       Impact factor: 6.940

9.  Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection.

Authors:  R Hofmann-Lehmann; E Holznagel; A Aubert; P Ossent; M Reinacher; H Lutz
Journal:  Vet Immunol Immunopathol       Date:  1995-05       Impact factor: 2.046

Review 10.  Feline panleukopenia. ABCD guidelines on prevention and management.

Authors:  Uwe Truyen; Diane Addie; Sándor Belák; Corine Boucraut-Baralon; Herman Egberink; Tadeusz Frymus; Tim Gruffydd-Jones; Katrin Hartmann; Margaret J Hosie; Albert Lloret; Hans Lutz; Fulvio Marsilio; Maria Grazia Pennisi; Alan D Radford; Etienne Thiry; Marian C Horzinek
Journal:  J Feline Med Surg       Date:  2009-07       Impact factor: 2.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.